Now that the FDA has carved out nonmetastatic, castration-resistant prostate cancer as a new disease state, the decision about whether to administer recently approved antiandrogen therapies in this setting hinges on the rate of increase in prostate-specific antigen levels and comorbidities.
Original Article: Strategies Take Shape for a New Disease State in Prostate Cancer